Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adamis Pharmaceuticl 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 USA

P: 858-997-2400

Description:

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.

Key Statistics

Overview:

Market Capitalization, $K 62,052
Shares Outstanding, K 61,438
Annual Sales, $ 15,090 K
Annual Net Income, $ -39,010 K
Last Quarter Sales, $ 5,760 K
Last Quarter Net Income, $ -7,740 K
60-Month Beta 1.38
% of Insider Shareholders 8.10%
% of Institutional Shareholders 12.12%
Float, K 56,462
% Float 91.90%

Growth:

1-Year Return -64.60%
3-Year Return -63.93%
5-Year Return -75.31%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 18.03%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/12/19
Earnings Per Share ttm -0.84
EPS Growth vs. Prev Qtr 15.79%
EPS Growth vs. Prev Year 44.83%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-17 on 12/13/13

ADMP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -4.09
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -86.04
Return-on-Assets (Before Tax) -67.11
Profit Margin % -258.52
Net Margin % N/A
Debt/Equity 0.05
Price/Sales 3.62
Price/Cash Flow N/A
Price/Book 1.25
Book Value/Share 0.71
Interest Coverage -245.13
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar